Last reviewed · How we verify
Minoxidil 2% only
At a glance
| Generic name | Minoxidil 2% only |
|---|---|
| Sponsor | Merz Pharmaceuticals GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE1)
- Bioavailability Clinical Trial of Oral Minoxidil 1 mg (PHASE1)
- Hair Regeneration in Androgenetic Alopecia (NA)
- Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia (PHASE2)
- Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia (NA)
- A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (PHASE2)
- Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minoxidil 2% only CI brief — competitive landscape report
- Minoxidil 2% only updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI